<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599894</url>
  </required_header>
  <id_info>
    <org_study_id>QiXin1</org_study_id>
    <nct_id>NCT04599894</nct_id>
  </id_info>
  <brief_title>Reducing Postoperative Side Effect of Pregabalin</brief_title>
  <official_title>Effect of Application of Low Dose of Pregabalin in TJA Before the Day of Surgery on Reducing Postoperative Side Effect of This Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To see the effect of application of 37.5mg pregabalin in TJA before the day of surgery on&#xD;
      reducing postoperative side effect of this medicine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized controlled study was designed to be carried out by enrolling 40&#xD;
      patients underwent surgery for joint replacement from October 2020 to February 2021. The&#xD;
      experimental group: Oral administration of Pregabalin (37.5mg) at 8 am and 18 pm 1 d before&#xD;
      operation; oral administration of Pregabalin (75mg) 2h before operation; and oral&#xD;
      administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge&#xD;
      (n=20). The control group: Oral administration of Pregabalin (75mg) 2h before operation; and&#xD;
      oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to&#xD;
      discharge (n=20).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 21, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sedation</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>sedation evaluated by Richmond Agitation-Sedation Scale, the minimum and maximum values are -5 to 0, higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sedation</measure>
    <time_frame>postoperative day 2</time_frame>
    <description>sedation evaluated by Richmond Agitation-Sedation Scale, the minimum and maximum values are -5 to 0, higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sedation</measure>
    <time_frame>postoperative day 3</time_frame>
    <description>sedation evaluated by Richmond Agitation-Sedation Scale, the minimum and maximum values are -5 to 0, higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dizziness</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>number of cases that complained dizziness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dizziness</measure>
    <time_frame>postoperative day 2</time_frame>
    <description>number of cases that complained dizziness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dizziness</measure>
    <time_frame>postoperative day 3</time_frame>
    <description>number of cases that complained dizziness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of pain</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>Visual Analog Score for pain, the minimum and maximum values are 0 to 10, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of pain</measure>
    <time_frame>postoperative day 2</time_frame>
    <description>Visual Analog Score for pain, the minimum and maximum values are 0 to 10, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of pain</measure>
    <time_frame>postoperative day 3</time_frame>
    <description>Visual Analog Score for pain, the minimum and maximum values are 0 to 10, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>range of motion</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>degree of knee extension to flexion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>range of motion</measure>
    <time_frame>postoperative day 2</time_frame>
    <description>degree of knee extension to flexion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>range of motion</measure>
    <time_frame>postoperative day 3</time_frame>
    <description>degree of knee extension to flexion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional outcome</measure>
    <time_frame>postoperative 6 weeks</time_frame>
    <description>functional outcome evaluated by knee society score, the minimum and maximum values are 0 to 100, higher scores mean a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of Pregabalin (37.5mg) at 8 am and 18 pm 1 d before operation; oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>37.5mg Pregabalin + 75mg Pregabalin</intervention_name>
    <description>37.5mg pregabalin preoperatively + 75mg pregabalin postoperatively</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75mg Pregabalin</intervention_name>
    <description>75mg pregabalin postoperatively</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical diagnosis of knee osteoarthritis；&#xD;
&#xD;
          -  avascular necrosis of femoral head；&#xD;
&#xD;
          -  dysplasia of the hip joint.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of neuropathic pain or other chronic pain;&#xD;
&#xD;
          -  unable to cooperate, allergic to drugs used in this study；&#xD;
&#xD;
          -  intolerant of non-steroidal anti-inflammatory drugs, or had long-term opioid use;&#xD;
&#xD;
          -  ASA grade IV or above;&#xD;
&#xD;
          -  medical history of vertigo and other diseases that might induce dizziness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Qi, Dr.</last_name>
      <phone>+8615843073202</phone>
      <email>qixindoc@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pregabalin</keyword>
  <keyword>total joint arthroplasty</keyword>
  <keyword>side effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

